000165843 001__ 165843
000165843 005__ 20240229133154.0
000165843 0247_ $$2doi$$a10.1186/s12916-020-01776-7
000165843 0247_ $$2pmid$$apmid:33161898
000165843 0247_ $$2altmetric$$aaltmetric:93945391
000165843 037__ $$aDKFZ-2020-02419
000165843 041__ $$aeng
000165843 082__ $$a610
000165843 1001_ $$0P:(DE-HGF)0$$aRothenbacher, Dietrich$$b0$$eFirst author
000165843 245__ $$aContribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project.
000165843 260__ $$aHeidelberg [u.a.]$$bSpringer$$c2020
000165843 3367_ $$2DRIVER$$aarticle
000165843 3367_ $$2DataCite$$aOutput Types/Journal article
000165843 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1611838570_22973
000165843 3367_ $$2BibTeX$$aARTICLE
000165843 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000165843 3367_ $$00$$2EndNote$$aJournal Article
000165843 500__ $$a#EA:C070#
000165843 520__ $$aChronic kidney disease has emerged as a strong cardiovascular risk factor, and in many current guidelines, it is already considered as a coronary heart disease (CHD) equivalent. Routinely, creatinine has been used as the main marker of renal function, but recently, cystatin C emerged as a more promising marker. The aim of this study was to assess the comparative cardiovascular and mortality risk of chronic kidney disease (CKD) using cystatin C-based and creatinine-based equations of the estimated glomerular filtration rate (eGFR) in participants of population-based and disease cohorts.The present study has been conducted within the BiomarCaRE project, with harmonized data from 20 population-based cohorts (n = 76,954) from 6 European countries and 3 cardiovascular disease (CVD) cohorts (n = 4982) from Germany. Cox proportional hazards models were used to assess hazard ratios (HRs) for the various CKD definitions with adverse outcomes and mortality after adjustment for the Systematic COronary Risk Evaluation (SCORE) variables and study center. Main outcome measures were cardiovascular diseases, cardiovascular death, and all-cause mortality.The overall prevalence of CKD stage 3-5 by creatinine- and cystatin C-based eGFR, respectively, was 3.3% and 7.4% in the population-based cohorts and 13.9% and 14.4% in the disease cohorts. CKD was an important independent risk factor for subsequent CVD events and mortality. For example, in the population-based cohorts, the HR for CVD mortality was 1.72 (95% CI 1.53 to 1.92) with creatinine-based CKD and it was 2.14 (95% CI 1.90 to 2.40) based on cystatin-based CKD compared to participants without CKD. In general, the HRs were higher for cystatin C-based CKD compared to creatinine-based CKD, for all three outcomes and risk increased clearly below the conventional threshold for CKD, also in older adults. Net reclassification indices were larger for a cystatin-C based CKD definition. Differences in HRs (between the two CKD measures) in the disease cohorts were less pronounced than in the population-based cohorts.CKD is an important risk factor for subsequent CVD events and total mortality. However, point estimates of creatinine- and cystatin C-based CKD differed considerably between low- and high-risk populations. Especially in low-risk settings, the use of cystatin C-based CKD may result in more accurate risk estimates and have better prognostic value.
000165843 536__ $$0G:(DE-HGF)POF3-323$$a323 - Metabolic Dysfunction as Risk Factor (POF3-323)$$cPOF3-323$$fPOF III$$x0
000165843 588__ $$aDataset connected to CrossRef, PubMed,
000165843 7001_ $$aRehm, Martin$$b1
000165843 7001_ $$aIacoviello, Licia$$b2
000165843 7001_ $$aCostanzo, Simona$$b3
000165843 7001_ $$aTunstall-Pedoe, Hugh$$b4
000165843 7001_ $$aBelch, Jill J F$$b5
000165843 7001_ $$aSöderberg, Stefan$$b6
000165843 7001_ $$aHultdin, Johan$$b7
000165843 7001_ $$aSalomaa, Veikko$$b8
000165843 7001_ $$aJousilahti, Pekka$$b9
000165843 7001_ $$aLinneberg, Allan$$b10
000165843 7001_ $$aSans, Susana$$b11
000165843 7001_ $$aPadró, Teresa$$b12
000165843 7001_ $$aThorand, Barbara$$b13
000165843 7001_ $$aMeisinger, Christa$$b14
000165843 7001_ $$aKee, Frank$$b15
000165843 7001_ $$aMcKnight, Amy Jayne$$b16
000165843 7001_ $$aPalosaari, Tarja$$b17
000165843 7001_ $$aKuulasmaa, Kari$$b18
000165843 7001_ $$aWaldeyer, Christoph$$b19
000165843 7001_ $$aZeller, Tanja$$b20
000165843 7001_ $$aBlankenberg, Stefan$$b21
000165843 7001_ $$aKoenig, Wolfgang$$b22
000165843 7001_ $$aconsortium, BiomarCaRE$$b23$$eCollaboration Author
000165843 773__ $$0PERI:(DE-600)2131669-7$$a10.1186/s12916-020-01776-7$$gVol. 18, no. 1, p. 300$$n1$$p300$$tBMC medicine$$v18$$x1741-7015$$y2020
000165843 909CO $$ooai:inrepo02.dkfz.de:165843$$pVDB
000165843 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000165843 9131_ $$0G:(DE-HGF)POF3-323$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vMetabolic Dysfunction as Risk Factor$$x0
000165843 9141_ $$y2020
000165843 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC MED : 2018$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2020-09-05
000165843 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBMC MED : 2018$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-05
000165843 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-05
000165843 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000165843 980__ $$ajournal
000165843 980__ $$aVDB
000165843 980__ $$aI:(DE-He78)C070-20160331
000165843 980__ $$aUNRESTRICTED